We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 32

CIPO updates guidance on medical use claims

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 23 2015

On March 18, 2015 the Canadian Intellectual Property Office issued a practice notice containing revised examination practice guidelines pertaining to

Expert opinion as to what “one would expect” is speculation, not evidence

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice

Eli Lilly files notice of arbitration in $500m NAFTA dispute against Canada

  • Bereskin & Parr LLP
  • -
  • Canada, Global
  • -
  • September 23 2013

In the past 10 years, there has been a significant increase in the number of Canadian pharmaceutical patents, which have been invalidated by the

The Myriad decision: what is the impact?

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

Supreme Court amends earlier decision: Viagra patent not void

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 6 2013

In Teva Canada Ltd v Pfizer Canada Inc, the Supreme Court of Canada (the "SCC") held Pfizer's Canadian Patent No. 2,163,446 (the '446 Patent) to be

What to expect when you are expecting to launch a drug in Canada regulatory overview

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 2 2015

This article provides a brief overview of key regulatory issues to be aware of when marketing a drug in Canada. Price Regulation and Reimbursement

Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of

Securing IP in stem cells

  • Bereskin & Parr LLP
  • -
  • Canada, USA
  • -
  • April 12 2013

Stem cells are at the centre of research into regenerative medicine. They have the ability to continuously produce newly differentiated cells and